Prosecution Insights
Last updated: November 04, 2026
Application No. 19/068,146

Oral Rapamycin Nanoparticle Preparations and Use

Non-Final OA §112§DOUBLEPATENT
Filed
Mar 03, 2025
Priority
Dec 31, 2013 — provisional 61/922,800 +7 more
Examiner
FAY, ZOHREH ALEMZADEH
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rapamycin Holdings Inc.
OA Round
1 (Non-Final)
52%
Grant Probability
Moderate
1-2
OA Rounds
1y 7m
Est. Remaining
46%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
589 granted / 1129 resolved
-7.8% vs TC avg
Minimal -6% lift
Without
With
+-6.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
59 currently pending
Career history
1194
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
51.3%
+11.3% vs TC avg
§102
10.7%
-29.3% vs TC avg
§112
20.8%
-19.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1129 resolved cases

Office Action

§112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-20 are presented for examination. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 3 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 is indefinite as to the terms “ABT-578, AP-23675, AP-23573, AP-23841" for rapamycin analogs. Such terms fail to identify the chemical structure or names of the analogs. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are drawn to the "a polymer" and "a micelle- inducing compound". MPEP § 2163 states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed. correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. Scope of the claims: The claims are very broad. They are drawn to "a polymer" and "a micelle-inducing compound". Therefore, to meet the written description requirement of 35 U.S.C. § 112, first paragraph, the specification must disclose a representative number of species that meet both the structural and functional limitations of the genus or the specification and/or the prior art must identify the structural elements that correlate to the claimed function in a manner that demonstrates to one of ordinary skill in the art that Applicant was in possession of the claimed genus at the time the application was filed Actual Reduction to Practice: MPEP § 2163 states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. In the instant case, the guidance provided is limited to examples of a few analogs of rapamycin, a few polymers and a few micelle-inducing compounds. Method of Making: the instant specification also fails to provide an adequate description as how a polymer and a micelle- inducing compound is made. The Applicant's specification little guidance as to which polymer, which micelle-inducing agent and which rapamycin analog encompassed by the claims would retain the desired activity. Thus, given the unpredictability in the art and the lack of guidance in the specification regarding making/using any compounds encompassed by the genus it is not possible for one of ordinary skill in the art to determine which compounds would be useful in the claimed composition. Sufficient relevant identifying characteristic: MPEP § 2163 states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination thereof. Functional characteristics when coupled with a known or disclosed correlation between function and structure: The specification does not describe a general correlation between structure and function for the claimed genus. The structure of any polymer, any micelle-forming composition and any rapamycin analog is vastly different one from another. There is no established correlation between the structure of any existing compound covered by the genus and any others that might be discovered in the future and the claimed function. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 12/239737. Although the claims at issue are not identical, they are not patentably distinct from each other because they overlap. The claims of the instant application are drawn to a particulate pharmaceutical preparation, comprising: a) a solid excipient matrix; b) an enteric material, wherein said enteric material remains intact until it reaches the near- neutral to basic conditions of the alimentary canal of a mammalian subject; c) nanoparticles dispersed within said solid excipient matrix, said nanoparticles comprising: 1) a micelle-inducing compound, said micelle-inducing compound comprising an amphipathic compound; and 2) rapamycin or an analog of rapamycin contained within micelles formed by said amphipathic compound. The claims of the U.S. Patent are drawn to A particulate pharmaceutical preparation, comprising: a) an enteric coating material, having characteristics such that it remains intact until it reaches the near-neutral to basic conditions of targeted portions of the alimentary canal of a mammalian subject, and then dissolves; b) a solid excipient matrix; and c) nanoparticles dispersed within said solid excipient matrix, said nanoparticles comprising: 1) a micelle-inducing compound, said micelle-inducing compound comprising an amphipathic compound; and 2) a pharmaceutically active core comprising rapamycin or an analog of rapamycin; d) said micelle-inducing compound naturally inducing formation of micelles, said micelles having properties that promote stability of said rapamycin or said analog of rapamycin when said nanoparticles are dispersed within said solid excipient matrix. The claims of the instant application and the U.S. patent are within the scope of each other. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 11/077,061. Although the claims at issue are not identical, they are not patentably distinct from each other because they overlap. The claims of the instant application are drawn to a particulate pharmaceutical preparation, comprising: a) a solid excipient matrix; b) an enteric material, wherein said enteric material remains intact until it reaches the near- neutral to basic conditions of the alimentary canal of a mammalian subject; c) nanoparticles dispersed within said solid excipient matrix, said nanoparticles comprising: 1) a micelle-inducing compound, said micelle-inducing compound comprising an amphipathic compound; and 2) rapamycin or an analog of rapamycin contained within micelles formed by said amphipathic compound. The claims of the U.S. Patent are drawn to A microparticle pharmaceutical preparation, comprising: a) an enteric coating comprising a solid excipient matrix, said solid excipient matrix comprising a polymer composition that remains intact when exposed to acidic conditions of the alimentary canal of an animal and that disintegrates in near-neutral to basic conditions of targeted portions of said alimentary canal, said polymer composition comprising a copolymer of methacrylic acid and methyl methacrylate; b) nanoparticles dispersed within said solid excipient matrix, said nanoparticles comprising: 1) a micelle-inducing compound, said micelle-inducing compound comprising sodium cholate; 2) a pharmaceutically active core comprising rapamycin or an analog of rapamycin; c) said micelle-inducing compound naturally inducing formation of micelles, said micelles having properties that promote stability of said rapamycin or said analog of rapamycin when said nanoparticles are dispersed within said solid excipient matrix. The claims of the instant application and the U.S. Patent are within the scope of each other. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 10,391,059. Although the claims at issue are not identical, they are not patentably distinct from each other because they overlap. The claims of the instant application are drawn to a particulate pharmaceutical preparation, comprising: a) a solid excipient matrix; b) an enteric material, wherein said enteric material remains intact until it reaches the near- neutral to basic conditions of the alimentary canal of a mammalian subject; c) nanoparticles dispersed within said solid excipient matrix, said nanoparticles comprising: 1) a micelle-inducing compound, said micelle-inducing compound comprising an amphipathic compound; and 2) rapamycin or an analog of rapamycin contained within micelles formed by said amphipathic compound. The claims of the U.S. patent are drawn to a method of orally administering a rapamycin to an animal subject, including a human animal subject, comprising: a. preparing or otherwise obtaining a microparticle pharmaceutical preparation, comprising: i. a solid excipient matrix comprising a polymer composition that remains intact when exposed to acidic conditions of the alimentary canal of an animal of the type of said subject animal and that disintegrates when exposed to basic conditions of targeted portions of said alimentary canal, said polymer composition comprising a copolymer of methacrylic acid; and ii. nanoparticles dispersed within said solid excipient matrix, said nanoparticles comprising a micelle-inducing compound comprising sodium cholate and a pharmaceutically active core; iii. said pharmaceutically active core comprising a rapamycin; iv. said micelle-inducing compound naturally inducing formation of micelles within a solution of said micelle-inducing compound, said micelles having properties that promote stability of said rapamycin when said nanoparticles are dispersed within said matrix; and b. orally administering said preparation to said animal subject multiple times per week over a multi-week duration, in efficacious amounts, wherein said animal subject is in need of or treatment, or delayed progression, of one or more oncologic, neurologic or autoimmune maladies. The composition of the instant application within the scope of the claims of the U.S. Patent. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZOHREH A FAY whose telephone number is (703)756-1800. The examiner can normally be reached Monday-Friday 9:30AM-6:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ZOHREH A FAY/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Mar 03, 2025
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766096
HIGH CONCENTRATION PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST FOR OPHTHALMIC DELIVERY
3y 1m to grant Granted Oct 20, 2026
Patent 12767616
COMPOUND LIQUID FERTILIZER
2y 10m to grant Granted Oct 20, 2026
Patent 12758549
HYDROGEL COMPOSITION AND USES THEREOF IN THE PREVENTION AND/OR TREATMENT OF SKIN DAMAGE CAUSED BY RADIATION
3y 2m to grant Granted Oct 13, 2026
Patent 12758490
HYDROGEL IMPLANTS FOR LOWERING INTRAOCULAR PRESSURE
2y 11m to grant Granted Oct 13, 2026
Patent 12751975
ANTI-INFLAMMATORY AGENT AND METHOD OF PRODUCING EXTRACELLULAR VESICLE HAVING ANTI-INFLAMMATORY ACTION
4y 2m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
52%
Grant Probability
46%
With Interview (-6.2%)
3y 3m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1129 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month